We were exploring ways of developing peptides that bind selectively, and we were very successful at that, but then we confronted the problem that our short, 23-residue peptides are not promising therapeutic candidates primarily because they cannot get into cells, Keating says
Stopping points If side effects do not resolve with slower injection or dose reduction, the most common research-planning response is to pause, reassess, and consult a clinician before resuming
(5) J Vukojevic, M Milavi, D Perovi, S Ili, et al (2022)
Medical Nexus: Proof linking the primary service-connected disability to the secondary condition of plantar fasciitis
canettii C59 strain containing pJV53H in order to obtain metE and metH mutants in this strain following the same procedure explained above for M